Diagnoplex

# Diagnoplex: High-Level Overview

Diagnoplex is a Swiss diagnostic technology company developing non-invasive blood biomarker tests for early cancer detection, with an initial focus on colorectal cancer screening.[1][3] The company builds molecular assays using single-channel quantitative multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) technology to identify cancer biomarkers in blood samples.[1] Diagnoplex addresses a critical healthcare gap: while survival rates for colorectal cancer improve dramatically—up to 90%—when detected early, current screening methods suffer from low compliance due to their invasive nature.[6] The company serves healthcare systems and diagnostic laboratories seeking to improve cancer detection rates through accessible, patient-friendly screening solutions.

Diagnoplex has demonstrated meaningful traction in the European market, securing multiple financing rounds and establishing strategic partnerships. The company closed a CHF 10 million funding round and has partnered with Unilabs, a leading European diagnostic provider, to scale its molecular assay capabilities across the continent.[1][5] This combination of proprietary technology, clinical validation, and distribution partnerships positions Diagnoplex as a growing player in the precision diagnostics space.

# Core Differentiators

• Non-invasive testing approach: Blood-based biomarker detection eliminates the barriers to compliance associated with traditional colonoscopy-based screening
• Molecular precision: Single-channel quantitative multiplex RT-PCR technology enables detection of cancer-specific biomarkers with high specificity
• Early detection capability: The platform is designed to identify colorectal cancer at earlier, more treatable stages
• Strategic distribution: Partnership with Unilabs provides access to established European laboratory networks and patient populations

# Role in the Broader Tech Landscape

Diagnoplex operates within the broader shift toward liquid biopsy and non-invasive diagnostics, a trend driven by advances in molecular biology and growing demand for patient-centric healthcare solutions. The timing is particularly favorable: healthcare systems across Europe face pressure to improve cancer screening rates while managing costs, and patients increasingly prefer non-invasive alternatives. Diagnoplex's focus on colorectal cancer—one of the most prevalent cancers globally—addresses a market with substantial unmet need and regulatory tailwinds supporting innovation in screening technologies.

# Quick Take & Future Outlook

Diagnoplex is well-positioned to capture market share in European cancer screening as healthcare providers seek to modernize their diagnostic capabilities. The company's success will likely depend on clinical validation through prospective studies, regulatory approvals across key European markets, and the ability to scale manufacturing and distribution through partnerships like Unilabs. As precision diagnostics become increasingly central to preventive healthcare, Diagnoplex's non-invasive biomarker platform could evolve beyond colorectal cancer into broader oncology screening applications, potentially expanding its addressable market significantly.